E
INBS icon

Ergoteles’s Intelligent Bio Solutions INBS Stock Holding History

Ergoteles’s Portfolio INBS Stock Details INBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6
Closed -$9K – 1735
2022
Q2 		$9K Buy
+6
New +$10.1K ﹤0.01% 1592

Other funds holding INBS

GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ergoteles's INBS Position: Q3 2022 in Review

Ergoteles sold out of Intelligent Bio Solutions (INBS) in Q3 2022, closing a stake of 6 shares — an estimated $9K sold.

Ergoteles first reported a position in INBS in Q2 2022 and held it in 1 quarter. The position peaked at $9K in Q2 2022. 8 funds tracked by Wall St. Rank hold INBS as of Q3 2022.

  • Ergoteles reported no remaining Intelligent Bio Solutions position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 6 Intelligent Bio Solutions shares in Q3 2022, an estimated $9K.
  • Ergoteles first reported a position in Intelligent Bio Solutions in Q2 2022 and held it in 1 quarter.
  • Ergoteles's Intelligent Bio Solutions position peaked at $9K in Q2 2022.
  • 8 funds tracked by Wall St. Rank held Intelligent Bio Solutions as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.